https://www.yiliao.com/index.php?action=history&feed=atom&title=RAAS_%E9%80%9A%E8%B7%AF
RAAS 通路 - 版本历史
2026-04-18T16:32:08Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=RAAS_%E9%80%9A%E8%B7%AF&diff=318211&oldid=prev
223.160.138.37：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-04-17T08:10:55Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>RAAS 通路</strong>（肾素-血管紧张素-醛固酮系统，Renin-Angiotensin-Aldosterone System）是人体内调节血压、血容量以及电解质平衡的最重要内分泌调节轴。该通路通过一系列酶促反应将血管紧张素原转化为具有强效缩血管作用的<strong>[[血管紧张素 II]]</strong>，并最终诱导醛固酮分泌以促进钠水潴留。RAAS 的过度激活是原发性高血压、慢性心力衰竭及蛋白尿性肾病的核心驱动力。临床上，针对该通路的抑制剂（如 ACEI、ARB 及 MRA）已成为心血管和肾脏保护的基石方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.1em; font-weight: bold; letter-spacing: 1.2px;">[[RAAS 通路]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">核心效应受体：AGTR1 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">关键酶：Renin / ACE</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心基因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">REN, AGT, ACE, AGTR1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">Entrez ID (ACE)</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1636</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">UniProt (AGTR1)</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">P30556</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量 (AGT)</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 50-60 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要产物</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">血管紧张素 II, 醛固酮</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">生理效应</th><br />
<td style="padding: 12px; color: #b91c1c;">缩血管、排钾保钠、升压</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">生化机制：经典的级联反应</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
RAAS 通路的激活遵循严密的酶促顺序，主要包括以下步骤：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>肾素释放（启动）：</strong> 当肾灌注压下降、血钠降低或交感神经兴奋时，肾脏球旁细胞释放<strong>[[肾素]]</strong>（Renin）。</li><br />
<li style="margin-bottom: 12px;"><strong>初级转化：</strong> 肾素将肝脏产生的血管紧张素原（AGT）水解为血管紧张素 I（Ang I）。</li><br />
<li style="margin-bottom: 12px;"><strong>关键转换：</strong> 主要存在于肺血管内皮的<strong>[[血管紧张素转换酶]]</strong>（ACE）将 Ang I 转化为强效的血管紧张素 II（Ang II）。</li><br />
<li style="margin-bottom: 12px;"><strong>终端效应：</strong> Ang II 结合 <strong>[[AT1 受体]]</strong>，引起血管剧烈收缩并刺激肾上腺皮质分泌<strong>[[醛固酮]]</strong>。醛固酮作用于肾远曲小管，增加 Na+ 重吸收并排出 K+。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：RAAS 异常与病理结局</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 22%;">临床疾病</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">RAAS 表现</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">病理生理影响</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #334155;">典型并发症</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[原发性高血压]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">持续性过度激活</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">外周阻力增加，血容量扩张。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">左心室肥厚、脑卒中</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[糖尿病肾病]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">局部组织 RAAS 亢进</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">出球小动脉收缩，肾小球高压力、高滤过。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">大量蛋白尿、[[肾硬化]]</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[慢性心力衰竭]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">代偿性激活（恶性循环）</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">心脏前、后负荷增加，诱发心肌重塑。</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">心力衰竭急性加重</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：多靶点拦截方案</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对 RAAS 通路的不同环节，临床开发了多种干预药物以实现器官保护：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>ACEI（转换酶抑制剂）：</strong> 如<strong>[[培哚普利]]</strong>。减少 Ang II 生成，同时抑制缓激肽降解，具显著心肾获益。</li><br />
<li style="margin-bottom: 12px;"><strong>ARB（受体拮抗剂）：</strong> 如<strong>[[缬沙坦]]</strong>。直接拮抗 AT1 受体，避开了 ACE 途径之外的 Ang II 生成（如糜蛋白酶途径）。</li><br />
<li style="margin-bottom: 12px;"><strong>MRA（盐皮质激素受体拮抗剂）：</strong> 如<strong>[[螺内酯]]</strong>或新型非甾体 MRA <strong>[[非奈利酮]]</strong>。直接阻断醛固酮的致炎和致纤维化作用。</li><br />
<li style="margin-bottom: 12px;"><strong>ARNI（双靶点抑制剂）：</strong> <strong>[[沙库巴曲缬沙坦]]</strong>。结合了 ARB 与脑啡肽酶抑制剂，已成为 HFrEF 治疗的基石。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #ffffff; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155; list-style-type: none;"><br />
<li style="margin-bottom: 8px;"><strong>[[ACE2]]</strong>：RAAS 的反向调节轴，将 Ang II 转化为具扩血管作用的 Ang(1-7)。</li><br />
<li style="margin-bottom: 8px;"><strong>[[AT2 受体]]</strong>：Ang II 的另一种受体，主要介导抗增殖和扩血管效应。</li><br />
<li style="margin-bottom: 8px;"><strong>[[钠水潴留]]</strong>：RAAS 激活后导致的循环血量增加现象。</li><br />
<li style="margin-bottom: 12px;"><strong>[[TGF-β 信号通路]]</strong>：常由 Ang II 诱导激活，介导晚期的组织纤维化。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Hall JE, et al. (2016).</strong> <em>The Renin-Angiotensin System: Components and Functions.</em> <strong>[[Physiology]]</strong>. [Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该综述详尽阐述了 RAAS 从经典通路到局部组织系统的演变过程。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Atlas SA. (2007).</strong> <em>The Renin-Angiotensin System: Basic Concepts and Clinical Implications.</em> <strong>[[Nephrology Dialysis Transplantation]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：定义了现代高血压管理中阻断 RAAS 的生化逻辑。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
RAAS 通路：血压与代谢平衡调节 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">启动因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Low Perfusion]] • [[Hyponatremia]] • [[Sympathetic Activation]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键分子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Renin]] • [[Angiotensin II]] • [[Aldosterone]] • [[AT1 Receptor]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">临床药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ACEI]] • [[ARB]] • [[MRA]] • [[DRI (Aliskiren)]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">生理结局</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Blood Pressure Elevation]] • [[Sodium Retention]] • [[Cardiovascular Remodeling]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.37